Emzor Pharmaceutical Industries Ltd (Emzor), a number one mild within the Nigerian pharmaceutical sector, has introduced the profitable compensation of its inaugural Collection 1 Industrial Paper.
Initially issued in November 2024, beneath its ₦10 billion Industrial Paper Issuance Programme, the ₦5.13 billion notice matured on August 18, 2025, marking a major milestone within the firm’s capital markets journey. This fulfilment and the continued retention of its funding grade credit standing of A- with a secure outlook (GCR), additional reinforces Emzor’s credibility and monetary self-discipline in Nigeria’s funding panorama.
Past this monetary triumph, Emzor continues to drive innovation, high quality, self-reliance, and excellence in pharmaceutical manufacturing.
The Firm has efficiently scaled up Native API (Energetic Pharmaceutical Substances) Manufacturing with a $23 Million transformative funding. Located in Sagamu, Ogun State,
the $23 million API plant is the primary of its sort in Sub-Saharan Africa. This enterprise is ready to bolster Nigeria’s drug self-sufficiency by lowering import reliance and reducing manufacturing prices, particularly for important medicines like antimalarials and HIV/AIDS antiretrovirals.
The API Plant nearing completion, was initially slated for opening in Q1-2024, however the timeline has been revised to early 2026, owing to fiscal, financial, and regulatory complexities. Regardless of these pressures, the challenge is advancing swiftly, with over 90% of civil engineering works accomplished and demanding manufacturing gear already put in, The API R&D laboratory has already developed and synthesized 5 antimalarial API’s in anticipation of full-scale manufacturing.
Emzor Pharmaceutical continues to sustainably champion Drug Security with Modern Observe-and-Hint Know-how, demonstrating a steadfast dedication to high quality and client security, Emzor has rolled out a complicated ERP, Oracle, in addition to track-and-trace software program system throughout its provide chain. These options assist lean manufacturing, tighten stock administration and strengthen market surveillance, serving to to eradicate substandard and counterfeit drugs, particularly in underserved areas.
The Firm has remained unwavering in selling Manufacturing Resilience and Regional Outreach, at a current ECOWAS@50 summit in Lagos, Emzor reaffirmed its pivotal function in enhancing medication safety throughout the continent. Notably, the corporate now has over 200 registered merchandise manufactured throughout a number of manufacturing unit websites, and distributes to all Nigerian states and to West Africa, together with direct exports to Liberia and Sierra Leone.
The Firm commends authorities for insurance policies bolstering native pharma manufacturing. Emzor, is without doubt one of the beneficiaries of a landmark coverage transfer by Nigeria’s authorities, which exempts pharmaceutical uncooked supplies from import duties and VAT for 2 years. This regulatory assist goals to stimulate native manufacturing, making important medicines extra inexpensive.
This additionally provides to the daring and in depth backward integration technique that Emzor is vigorously pursuing. As well as, a brand new financial directive generally known as ‘The Nigeria-First Coverage’, permitted by President Bola Ahmed Tinubu, in Could this 12 months, mandates all Federal ministries, departments and companies to prioritise procurement of domestically manufactured items, enhancing the outlook for the availability of Emzor’s merchandise throughout public tenders.
Emzor’s well timed compensation of its debut industrial paper underscores its strong monetary administration, whereas its strategic initiatives—starting from cutting-edge infrastructure to digital integrity techniques, spotlight its management in Nigeria’s pharmaceutical evolution. As the corporate nears completion of its landmark API facility and continues to increase its footprint, Emzor stays on the vanguard of constructing resilient, accessible healthcare throughout Africa.
